83902-00-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Ethyl-4-formylimidazole is used as a building block for the preparation of various pharmaceutical compounds due to its chemical reactivity and structural properties that facilitate the development of new drugs.
Used in Agrochemical Industry:
In agrochemicals, 2-Ethyl-4-formylimidazole is used as a key intermediate in the synthesis of active ingredients for pesticides and other agricultural chemicals, contributing to crop protection and yield enhancement.
Used in Dye Industry:
2-Ethyl-4-formylimidazole is used as a precursor in the production of dyes, where its chemical structure plays a role in determining the color and properties of the final dye products.
Used in Corrosion Inhibition:
As a corrosion inhibitor, 2-Ethyl-4-formylimidazole is employed to protect metal surfaces from corrosion, extending the service life of equipment and structures in various industrial applications.
Used in Organic Synthesis:
2-Ethyl-4-formylimidazole is used as a versatile reagent in organic synthesis, enabling the creation of a wide range of organic compounds for research and commercial purposes.
Used in Research for Pharmacological Properties:
2-Ethyl-4-formylimidazole is used in research as a potential antitumor agent, with studies exploring its effects on tumor growth and its potential integration into cancer treatment protocols.

InChI:InChI=1/C6H8N2O/c1-2-6-7-3-5(4-9)8-6/h3-4H,2H2,1H3,(H,7,8)

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 1072-62-4 2-Ethylimidazole 

Relevant academic research and scientific papers

Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors

We have previously described the identification of indolin-2-one-5-carboxamides as potent PAK4 inhibitors. This study expands the structure-activity relationships on our original series by presenting several modifications in the lead compounds, 2 and 3. A series of novel derivatives was designed, synthesized, and evaluated in biochemical and cellular assay. Most of this series displayed nanomolar biochemical activity and potent antiproliferative activity against A549 and HCT116 cells. The representative compound 10a exhibited excellent enzyme inhibition (PAK4 IC50 = 25 nM) and cellular potency (A549 IC50 = 0.58 μM, HCT116 IC50 = 0.095 μM). An X-ray structure of compound 10a bound to PAK4 was obtained. Crystallographic analysis confirmed predictions from molecular modeling and helped refine SAR results. In addition, Compound 10a displayed focused multi-targeted kinase inhibition, good calculated drug-likeness properties. Further profiling of compound 10a revealed it showed weak inhibitory activity against various isoforms of human cytochrome P450.

Imidazole-based pinanamine derivatives: Discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus

We previously reported potent hit compound 4 inhibiting the wild-type influenza A virus A/HK/68 (H3N2) and A/M2-S31N mutant viruses A/WS/33 (H1N1), with its latter activity quite weak. To further increase its potency, a structure-activity relationship study of a series of imidazole-linked pinanamine derivatives was conducted by modifying the imidazole ring of this compound. Several compounds of this series inhibited the amantadine-sensitive virus at low micromolar concentrations. Among them, 33 was the most potent compound, which was identified as being active on an amantadine-sensitive virus through blocking of the viral M2 ion channel. Furthermore, 33 markedly inhibited the amantadine-resistant virus (IC50 = 3.4 μM) and its activity increased by almost 24-fold compared to initial compound, with its action mechanism being not M2 channel mediated.

LRRK2 INHIBITORS

Provided herein are compounds that inhibit or partially inhibit the activity of leucine rich repeat kinases. Also provided herein are methods of treatment of CNS disorders comprising administration of inhibitors of leucine rich repeat kinases.